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Abstract
Background: The incidence and mortality of hepatocellular cancer (HCC) complicating alcoholic
and non-alcoholic fatty liver diseases (ALD and NAFLD) is rising in western societies. Despite
knowing the at risk populations for HCC development, the lack of sensitive and specific means of
surveillance hampers disease detection at curable stages. The most widely used serum HCC
marker is alpha-fetoprotein (AFP), while PIVKA-II, glypican-3 (GP3) and Squamous Cell Carcinoma
Antigen -1 (SCCA-1) have been proposed as new biomarkers. Assessment of these HCC
biomarkers has largely been performed in patients with viral hepatitis. We conducted a cross
sectional study assessing the value of these serum proteins, as well a novel candidate biomarker -
follistatin – in patients with HCC arising on a background of ALD or NAFLD.
Methods: Pre-treatment serum samples from 50 patients with HCC arising on a background of
ALD (n = 31) or NAFLD (n = 19) were assessed by specific ELISA assay for PIVKAII, Glypican-3,
SCCA-1 and Follistatin. Results were compared and contrasted with a control patient group with
biopsy proven steatohepatitis-related cirrhosis (n = 41). The diagnostic accuracy of each of the
candidate biomarkers was evaluated using receiver operating characteristic (ROC) curve analysis,
reporting the area under the curve (AUC) and its 95% confidence interval (CI). Performance was
compared to that of the established biomarker, AFP.
Results: Serum levels of all proteins were assessed by specific ELISA assays. GP3, SCCA-1 and
follistatin had no HCC surveillance benefit in these patients. AFP and PIVKAII were superior to the
other markers, particularly in combination.
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Conclusion: We conclude that while novel means of surveillance are urgently required, the
combination of AFP and PIVKAII for HCC is an improvement on AFP alone in ALD/NAFLD
patients. Furthermore, our data in this homogenous subset of patients- particularly that confirming
no role for SCCA-1 – suggests that the choice of optimal biomarkers for HCC surveillance may be
determined by the aetiology of underlying chronic liver disease.
Background
Hepatocellular carcinoma (HCC) is a major health prob-
lem worldwide, with more than 500,000 cases diagnosed
annually [1]. While the incidence of HCC has reportedly
risen over the last 5–8 years, the survival of those affected
has not changed significantly in the last two decades [1-3].
This is related to both its late detection the lack of effective
therapies for advanced stage disease [4]. Up to 80% of
HCCs develop against a background of cirrhosis of the
liver and while we believe that surveillance of the at risk
cirrhotic population could aid earlier detection of the dis-
ease and decrease the cancer related mortality rate, our
present success is limited by the lack of sensitive biomar-
kers. Currently, standard surveillance includes a combina-
tion of 6 monthly abdominal ultrasound scan (USS) and
serum alphafetoprotein (AFP) measurement, but this
strategy does not reliably detect early disease. The diag-
nostic performance of AFP is inadequate[5] as it is only
elevated in 40–60% of cases, while abdominal USS is dif-
ficult in cirrhotic nodular livers and notoriously user
dependent[6]. Alternative serum biomarkers are being
actively sought and proposed candidates include Pro-
thrombin Induced by Vitamin K Absence (PIVKA-II), gly-
pican-3 (GP3), and more recently, Squamous Cell
Carcinoma Antigen -1 (SCCA-1).
PIVKA-II is an abnormal prothrombin identified as an
HCC biomarker in 1984 [7] and since reported elevated
most notably in advanced cases with portal vein invasion
[8,9]. It is proposed that PIVKA-II may be useful primarily
as a prognostic biomarker, predicting rapid tumour pro-
gression and a poorer prognosis [10]. The oncofetal anti-
gen glypican3 (GP3) is a heparan sulfate proteoglycan
that is expressed in more than 70% of HCC[11]. When
combined with AFP it has a sensitivity of up to 82% for
HCC detection on a background of viral hepatitis [12].
SCCA-1 is a member of the high molecular weight serine
protease family called serpins [13] initially reported ele-
vated in epithelial tumours such as the cancer of the head
[14] and more recently in the serum of individuals with
HCC and cirrhosis. [15]
On a global scale, viral causes of chronic liver disease are
the commonest predecessors of HCC and these proposed
biomarkers [16] have largely been studied in this disease
group. Our own HCC patients have tumours arising pre-
dominantly on a background of alcoholic (ALD) and
non-alcoholic fatty liver diseases (NAFLD). Here we
present the data on a cross-sectional study comparing the
efficacy of these markers, as well as a novel candidate
biomarker, Follistatin, for the diagnosis of HCC arising on
a background of steatohepatitis related cirrhosis. Follista-
tin is a secreted monomeric protein overexpressed in rat
and human liver tumours and reportedly contributing to
hepatocarcinogenesis by the inhibition of activins [17].
Follistatin mRNA was markedly overexpressed in HCC
cell line microarray studies performed in our own labora-
tory (unpublished data).
Our data indicate differences in biomarker performance
in NAFLD and ALD patients compared to performances
reported in viral hepatitis. Neither PIVKAII, GP3, SCCA-1,
nor the novel candidate Follistatin, has a role independ-
ent of AFP in HCC surveillance in steatohepatitis related
cirrhosis. We show that the combination of AFP and
PIVKAII is more valuable than AFP alone and suggest this
approach be adopted as standard surveillance in this dis-
ease group.
Methods
Patient serum samples
All patient serum and clinical information were collected
with patient consent after approval by The Newcastle and
North Tyneside Ethics Committee approved this study.
Patients were diagnosed as having HCC as per guidelines
proposed by the European Association for the Study of the
Liver [6]. Pre-treatment samples from 50 patients with
HCC, all of whom had an underlying cirrhosis, were
selected for study. Of these, 31 patients had alcoholic liver
disease (ALD) and 19 patients had NAFLD. The serum was
immediately separated by centrifugation and frozen at -
80°C. These serum samples were compared to an inde-
pendent group of 41 patients with biopsy proven ALD or
NAFLD cirrhosis. The diagnosis of NAFLD cirrhosis was
made in patients who had clinical features and liver biop-
sies compatible with NAFLD. Females and males consum-
ing greater than 14 or 21 units of alcohol per week
respectively were excluded from this category, as were any
individuals with viral or autoimmune liver diseases. The
presence of steatosis was necessary for the diagnosis to be
made, as was stage 4 fibrosis defined by modified Brunt
criteria[18]BMC Cancer 2008, 8:200 http://www.biomedcentral.com/1471-2407/8/200
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The biochemical serum tests, including serum AFP, were
measured using routine automated methods in the Bio-
chemistry Laboratory at the Freeman Hospital, Newcastle
upon Tyne. No patient positive for either HBsAg or HCV
were included in this study.
Western blotting and serum ELISA assays
PIVKA-II was measured using a commercially available
ELISA kit (Asserachrom PIVKAII kit, Stago, France),
according to the manufacturer's instructions. The detec-
tion limit is 01 ng/ml. The cut-off value was set as 20 ng/
ml for differentiation between HCC and cirrhosis based
on the findings in this study. Glypican-3 was measured
using commercially available ELISA kit (Biomosaics lim-
ited) following the manufacturer's protocol. Serum SCCA-
1 was measured as previously described an ELISA kit pur-
chased from Xeptagen (Xeptagen, Naples, Italy) and fol-
lowing the manufacturer's instructions. [15]
Follistatin was selected for study based on its marked
expression in HCC cell lines on microarray analysis and
literature review identifying it as a secretory protein with a
previously suspected role in hepatocarcinogenesis. Ten
samples each from patients with NAFLD, NAFLD and cir-
rhosis, or NAFLD with cirrhosis and HCC were
immunedepleted by multiple affinity removal (MARS
HPLC column;Agilent technologies) and desalted using 5
K molecular weight cut off spin filters (Agilent technolo-
gies). Subsequently, 50 μg of protein was separated by
SDS-PAGE and transferred to PVDF membrane (250 mA
for 90 min). The membrane was then probed with mouse
anti-follistatin antibody (R&D Systems) at 1:500 dilution
at room temperature overnight. After washing in Tris Buff-
ered Saline (0.1% Tween), the membranes were incubated
with secondary peroxidase conjugated rabbit anit-mouse
immunoglobulin and developed using ECL (Amersham).
Subsequently, a direct ELISA assay for quantitative analy-
sis, was developed using different concentrations of serum
(raw; 1:10; 1:50; 1:100: 1:1000) with serial dilution of pri-
mary antibody. Optimal conditions were using a raw
serum dilution of 1:10 and an antibody dilution of 1:250.
Statistical analysis
Quantitative variables were expressed as mean and stand-
ard deviation. Comparison between groups was by Pear-
son Chi-square, Wilcoxon or Student's t-test, as
appropriate. Qualitative variables were expressed as count
and percentage and comparisons between independent
groups was by Pearson Chi-square. The diagnostic accu-
racy of each of the candidate biomarkers was evaluated
using receiver operating characteristic (ROC) curve analy-
sis, reporting the area under the curve (AUC) and its 95%
confidence interval (CI). The diagnostic cut-off and the
related sensitivity and specificity were determined. Statis-
tical analysis was performed with SAS V8.2 software for
PC, MedCalc version 7.4.3.0, as well as SPPS version 14.
Results
Serum AFP, PIVKA-II, GP3 and SCCA-1 levels were deter-
mined in 50 patients with HCC arising in a background of
ALD or NAFLD cirrhosis. A control group of 41 patients
with cirrhosis from ALD/NAFLD was used for compari-
son. The clinical characteristics of the patients in these
groups are shown in Table 1.
Serum AFP and PIVKAII as biomarkers of HCC in 
steatohepatitis related cirrhosis
The median AFP value determined in our patients with
HCC and those with cirrhosis were 92.4 ng/ml and 5.96
ng/ml respectively. These data are represented using a log
scale in Figure 1A and also summarised in Table 2. This
difference was statistically significant (p value 0.0004).
The ROC curve analysis (Figure 2A) confirmed an area
under curve of 0.71 (CI 95% 0.61 – 0.8), with a cut-off
value of 15 giving a sensitivity of 58% (CI95% 43.2%
71.8%) and a specificity of 100% (CI 95% 91.3 – 100).
Mean PIVKA-II levels were also significantly different
between patients with HCC and liver cirrhosis, as shown
in 1B and Table 2. The median value in the former was
42.74 ng/ml and in the latter 7.8 ng/ml (interquartile
range: 2.8 – 17.8). The area under the ROC curve was 0.81
(CI95% 0.715 – 0.886) with a cut-off 20.24 ng/ml. This
predicted a sensitivity of 79.6%. (CI95% 65.7% – 89.7%)
and a specificity of 80.5% (CI95% 65.1 – 91.2%). As
shown in Figure 1F, the level of PIVKAII is significantly
raised in patients with tumours >5 cm in size (n = 24) rel-
ative to those 3–5 cm in size (n = 23) (ANOVA p = 0.001).
In fact, the level from tumours 3–5 cm in size was not sig-
nificantly different from the level in patients with cirrho-
sis alone. While there was similarly a difference between
Table 1: Clinical characteristics of the patients with cirrhosis and 
cirrhosis plus HCC
Cirrhosis HCC
Number 41 50
Age (years) 54.3 ± 9.62 67.5 ± 12.02
Male:Female 28:13 40:10
ALD:NAFLD 33:08 30:20
Childs-Pugh A:B:C 22:14:05 27:18:05
Portal vein invasion NA 8
Single nodule NA 22
Two nodules NA 10
≥ 3 nodules NA 18
The difference in age between HCC and cirrhosis alone patients was 
statistically significant (p < 0.001; Pearson Chi square test), while 
there was no significant difference between sex or Child-Pugh Stage in 
the two groups. NA – not applicable.BMC Cancer 2008, 8:200 http://www.biomedcentral.com/1471-2407/8/200
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Serum levels of Candidate Biomarkers in cirrhotic patients with and without HCC Figure 1
Serum levels of Candidate Biomarkers in cirrhotic patients with and without HCC. Box plots comparing levels of 
AFP, PIVKAII, GP3, SCCA-1 and Follistatin are shown. Levels are presented as ng/ml, except for AFP where the log data are 
presented in order to accommodate the wide range. The mean between the two groups is significantly different for both AFP 
and PIVKAII. For the latter, this is predominantly a result of a marked increase in levels in individuals with tumours greater than 
5 cm in size.BMC Cancer 2008, 8:200 http://www.biomedcentral.com/1471-2407/8/200
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ROC Curve analyses of the candidate biomarkers Figure 2
ROC Curve analyses of the candidate biomarkers. The diagnostic accuracy of each candidate biomarker, in terms of 
sensitivity and specificity, are presented after receiver operating characteristic (ROC) curve analysis. In figures 2A and 2B, cor-
responding to AFP and PIVKAII, the area under the curve is markedly better than for the other markers.BMC Cancer 2008, 8:200 http://www.biomedcentral.com/1471-2407/8/200
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these two size groups using AFP (7369 +/- 14361 ng/ml; n
= 36 versus 2417 +/- 8889 ng/ml; n = 13), the difference
was not statistically significant. Serum AFP therefore is
better at specifically detecting early malignant disease
than PIVKAII. However, the combination of serum AFP
and PIVKA-II in these patients is better than either alone,
with a combined sensitivity of 94% and a specificity of
just over 80%, as shown in Table 3.
Serum GP3 and SCCA-1 have no role in HCC surveillance 
in steatohepatitis-related cirrhosis
The data for GP3 and SCCA-1 in this group of ALD/
NAFLD patients with and without HCC is also presented
in Figures 1 and 2 and Table 2 and 3. These data demon-
strate that neither had any value in HCC detection in this
group of patients. While their expression was elevated in
the serum of patients with chronically diseased livers and
HCC, there was no significant difference between the lev-
els detected in cirrhotic patients with and without a can-
cer.
Follistatin is raised in the serum of individuals with cirrhosis 
and HCC, but its specificity for HCC is poor
Levels of follistatin were studied in immune depleted
serum from individuals with either NAFLD (n = 10),
NAFLD with cirrhosis (n = 10), or NAFLD with cirrhosis
and HCC (n = 10) by western blot analysis. Representative
data from 24 of these individuals is presented in Figure 3.
While there was little evidence of follistatin in the serum
of individuals with NAFLD without significant fibrosis or
HCC, it was detectable in all indiduals with HCC as well
as some individuals with cirrhosis and no HCC. We went
on to develop an ELISA assay for more quantitative raw
serum analysis between the latter two groups. Unfortu-
nately, while follistatin is clearly increased in individuals
with cirrhotic NAFLD, it fails to distinguish between those
with and without HCC, as shown in Figures 1E and 2E.
Discussion
The increasing incidence of HCC[3], compounded by the
fact that the majority of these tumours are diagnosed at a
late stage when curative treatments are not possible[19],
Table 2: Levels of candidate biomarkers (ng/ml) as detected by specific ELISA assays
Cirrhosis Cirrhosis + HCC
Mean ± S.D. median Mean ± S.D. median
AFP 5.96 ± 2.65 5.00 5934.66 ± 13025.02 92.50
PIVKAII 23.47 ± 59.69 7.83 135.17 ± 168.96 42.75
GP3 125.41 ± 281.05 29.62 161.41 ± 422.33 56.57
Follistatin 72.41 ± 76.16 50.20 87.33 ± 131.31 61.35
The mean level between cirrhotic patients versus cirrhotic patients with cancer was significantly different in the cases of AFP and PIVKAII (p = 0.004 
and p < 0.001 respectively, Wilcoxon). There was no significant difference between levels for GP3, CD5L or Follistatin.
Table 3: Performance of combinations of candidate biomarkers
Combination TP FP TN FN sensitivity (HCC = 50) specificity (LC = 41) TPP TPN LR
afp 28 0 41 22 56.00% 100.00% 100.0% 65.10% -
afp+piv 47 8 33 3 94.00% 80.50% 85.50% 91.70% 4.82
piv 39 8 33 11 78.00% 80.50% 83.00% 75.00% 4
afp+scca 36 11 30 14 72.00% 73.20% 76.60% 68.20% 2.68
afp+piv+scca 45 16 25 5 90.00% 61.00% 73.80% 83.30% 2.31
piv+scca 42 16 25 8 84.00% 61.00% 72.40% 75.80% 2.15
gcp+scca 36 16 25 14 72.00% 61.00% 69.20% 64.10% 1.85
afp+gcp 41 22 19 9 82.00% 46.30% 65.10% 67.90% 1.53
afp+piv+gcp 48 27 14 2 96.00% 34.10% 64.00% 87.50% 1.46
gcp+piv 46 27 14 4 92.00% 34.10% 63.00% 77.80% 1.4
all 48 31 10 2 96.00% 24.40% 60.80% 83.30% 1.27
gcp 34 22 19 16 68.00% 46.30% 60.70% 54.30% 1.27
gcp+piv+scca 47 31 10 3 94.00% 24.40% 60.30% 76.90% 1.24
afp+gcp+scca 36 28 13 14 72.00% 31.70% 56.30% 48.10% 1.05
scca 9 11 30 41 18.00% 73.20% 45.00% 42.30% 0.67
The true and false positive (TP and FP), as well as true and false negative (TN and FN) for each candidate either alone or in combination is 
presented, along with sensitivity, specificity, true percentage positive (TPP) and true percentage negative (TPN) values and the liklihood ratio (LR). 
The LR is the ratio of true and false positives (sensitivity and 1-specificity respectively), where higher values reflect the probability of a better 
performance.BMC Cancer 2008, 8:200 http://www.biomedcentral.com/1471-2407/8/200
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has prompted the international community into perform-
ing regular surveillance of high risk individuals. Unfortu-
nately, surveillance programmes are hindered by the poor
performance of the commonly used serum marker,
namely AFP[6], even in combination with abdominal
USS. A tremendous amount of effort has been and contin-
ues to be applied to the search for improved HCC biomar-
kers. As yet, none has proved superior to AFP in
performance, but in combination some may have compli-
mentary roles in HCC arising on a background of viral
hepatitis [20]. Our own particular concern relates to the
marked increase in the prevalence of ALD and NAFLD
related HCC on our own unit.
In our study, serum AFP performs moderately well as a
biomarker of HCC in ALD/NAFLD patients, with a sensi-
tivity of 58% (15 ng/ml) in combination with a specificity
of 100%. The AASLD recommended cut off level for diag-
nosis of HCC is 200 ng/ml [21], although lower levels,
particularly if rising, should be deemed suspicious and
followed very carefully. In ALD/NAFLD patients, where a
mild to moderately elevated but stable AFP level similar to
that occasionally observed in individuals with viral hepa-
titis is rare, it may be possible to attach a more sinister
connotation to much lower levels of expression. While
this data is encouraging, the sensitivity of AFP is not good
enough for it to be used in isolation, as over a third of can-
cers will be missed.
Both the sensitivity and specificity for PIVKAII as an HCC
biomarker were in the order of 80% at a level of 20 ng/ml.
The addition of PIVKAII serum analysis to that of AFP
increases the combined sensitivity to 94%. While this is at
the modest expense of the specificity (reduced to 80.5%),
the combination of both AFP and PIVKAII analyses may
well be justified in our patients. It should be noted, how-
ever, that the added benefit is only in the detection of
more advanced disease – as indicated in previous viral
hepatitis studies and confirmed in our own NAFLD/ALD
patients -the encouraging performance of PIVKA-II is pre-
dominantly a result of detection of larger, more advanced
cancers.
Assessment of the other candidate biomarkers was disap-
pointing. Both the sensitivity and specificity of GP3 were
poor in our patient set, indicating that it has no role at all
in the surveillance of HCC in individuals with steatohep-
atitis related cirrhosis. Follistatin is an expressed transcript
in fetal liver and has previously been identified by micro-
array as an up-regulated gene in HCC relative to dysplastic
nodules [22]. Although we had high hopes for this activin
antagonising protein, [23] based on both our preliminary
microarray data and a pilot study in immune depleted
sera, the ELISA data assessing its discriminatory function
between cirrhotic individuals with and without HCC was
poor. The discrepancy between the western and ELISA
data is most likely a result simply of assessing a greater
number of patients using the latter method, but it is also
that follistatin, or an isoform of it, was enriched during
the column preparation phase of the serum of HCC
patients assessed by western blotting. Perhaps the most
surprising of results, however, in this homogenous group
of patients with steatohepatitis related HCC, was the dis-
appointing performance of SCCA-1. SCCA-1 has previ-
ously shown promise, particularly as an AFP
complementary biomarker, in viral hepatitis related HCC
[24,25]. In our study in NAFLD/ALD, however, there was
no significant difference between levels in patients with
and without HCC and while the combination with AFP
does modestly improve its sensitivity (78% from 56%),
this is at an unacceptable cost to specificity (73% from
100%). Why this serum protein should be significantly
elevated in the serum of HCV related HCC patients rela-
tive to HCV cirrhosis alone, and not similarly elevated in
steatohepatitis related HCC patients relative to steatohep-
atitis cirrhosis alone is unclear. It is possible that the study
of these novel candidate biomarkers complexed to immu-
noglobulins, rather than the study of their free forms, may
yet improve their performance, as has been shown for
other biomarkers [26]. Whether or not there is room for
improvement, however, our SCCA-1 data clearly indicate
that as we come to consider further candidate biomarkers
it is important to assess HCC arising in different disease
backgrounds independently when performing validation
studies.
Conclusion
In summary, while we propose the combination of AFP
and PIVKAII for HCC surveillance in NAFLD/ALD
patients, the search for novel biomarkers of early HCC dis-
ease should continue.
Follistatin is detectable in serum in patients with NAFLD  related HCC Figure 3
Follistatin is detectable in serum in patients with 
NAFLD related HCC. Immune depleted serum samples 
from individuals with non-fibrotic NAFLD (N), NAFLD cir-
rhosis (Ci), and NAFLD cirrhosis with cancer (C) have been 
separated by SDS-PAGE and analysed by western blot. The 
majority of HCC patients had detectable levels of follistatin 
in their serum, as did one or two individuals with NAFLD cir-
rhosis and no cancer.BMC Cancer 2008, 8:200 http://www.biomedcentral.com/1471-2407/8/200
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